About

The Braden Scale is the most widely validated clinical instrument for predicting pressure ulcer (decubitus) development in adult patients. Developed by Bergstrom and Braden in 1987, it quantifies risk across six subscales: Sensory Perception, Moisture, Activity, Mobility, Nutrition, and Friction & Shear. The total score ranges from 6 to 23. Lower scores indicate higher risk. A score ≤ 18 is generally accepted as the threshold for initiating preventive interventions, though ICU populations often use ≤ 16. Misclassification carries direct consequences: understaging delays turning schedules and specialty surface deployment, increasing hospital-acquired pressure injury (HAPI) rates and associated costs averaging $10,700 - $21,400 per stage III/IV wound (AHRQ data).

This calculator implements the standard Braden scoring matrix with five risk strata. It does not replace clinical judgment. Scores should be reassessed every 24-72 hours for acute care and weekly for long-term care. Note: the scale was validated on adult populations. Pediatric patients require the Braden Q variant, which this tool does not cover. Pro tip: always re-score after any significant change in patient status (surgery, onset of fever, hemodynamic instability).

Formulas

The Braden Scale total is a simple additive model across six independent subscales:

B = SP + M + A + Mob + N + FS

Where B = Braden total score (6 - 23), SP = Sensory Perception (1 - 4), M = Moisture (1 - 4), A = Activity (1 - 4), Mob = Mobility (1 - 4), N = Nutrition (1 - 4), FS = Friction & Shear (1 - 3).

Risk stratification follows a piecewise classification:

{

Very High Risk if B ≤ 9High Risk if 10 ≤ B ≤ 12Moderate Risk if 13 ≤ B ≤ 14Mild Risk if 15 ≤ B ≤ 18No Risk if B ≥ 19

The maximum possible score is 23 (no risk). The minimum is 6 (maximum risk across all domains). Note that Friction & Shear caps at 3, not 4, which makes the theoretical maximum 23 rather than 24.

Reference Data

Risk Category	Score Range	Recommended Interventions	Reassessment Frequency
Very High Risk	≤ 9	Specialty mattress, q1-2h repositioning, moisture management, nutrition consult, heel suspension	Every 24 hours
High Risk	10 - 12	Pressure redistribution surface, q2h turning schedule, incontinence management, dietary assessment	Every 24-48 hours
Moderate Risk	13 - 14	Foam overlay, q2-3h repositioning, skin inspection each shift, nutrition screening	Every 48-72 hours
Mild Risk	15 - 18	Standard mattress with overlay consideration, routine turning, skin checks, encourage mobility	Every 72 hours
No Risk	19 - 23	Standard care, encourage ambulation, maintain nutrition, routine skin assessment	Weekly or per policy
Subscale Reference
Sensory Perception	1 - 4	Ability to respond meaningfully to pressure-related discomfort
Moisture	1 - 4	Degree to which skin is exposed to moisture
Activity	1 - 4	Degree of physical activity
Mobility	1 - 4	Ability to change and control body position
Nutrition	1 - 4	Usual food intake pattern
Friction & Shear	1 - 3	Friction: resistance to motion. Shear: gravitational sliding force
Population-Specific Cutoffs
General Acute Care	≤ 18	Sensitivity ~83%, Specificity ~64% (Bergstrom et al., 1998)
ICU / Critical Care	≤ 16	Higher specificity in hemodynamically unstable patients
Long-Term Care	≤ 18	Weekly reassessment; nutrition subscale often most predictive
Home Health	≤ 18	Caregiver education critical; assess on each visit
Perioperative	≤ 20	Procedures > 4 hours significantly increase risk regardless of score

Frequently Asked Questions

The original Braden Scale developers determined that Friction & Shear could be adequately discriminated into three clinically meaningful levels: Problem (1), Potential Problem (2), and No Apparent Problem (3). A fourth level did not add predictive validity in their validation studies. This asymmetry means the maximum total score is 23, not 24.

The most commonly cited threshold is a total Braden score ≤ 18 for general acute care settings. However, ICU patients may benefit from a lower threshold of ≤ 16 due to higher baseline risk from immobility, vasopressor use, and edema. Institutional protocols vary. The NPUAP/EPUAP guidelines recommend that any patient identified as "at risk" should receive a bundle of preventive measures including pressure redistribution, repositioning schedules, moisture management, and nutritional optimization.

Nutrition is one of the strongest independent predictors within the Braden subscales. Serum albumin < 3.5 g/dL and prealbumin < 15 mg/dL correlate with impaired wound healing and increased pressure injury incidence. A patient scoring 1 (Very Poor) on the Nutrition subscale - meaning NPO and/or inadequate intake for > 5 days - should trigger an automatic dietary consult regardless of total Braden score. Studies show that nutritional supplementation (protein ≥ 1.25 g/kg/day, caloric adequacy, and micronutrient support) can reduce pressure injury incidence by 25%.

No. The standard Braden Scale was validated exclusively on adult populations (≥ 18 years). Pediatric patients require the Braden Q scale, which modifies the subscales to account for developmental differences in mobility, activity, and nutrition. Neonates in the NICU often use the Neonatal Skin Risk Assessment Scale (NSRAS). Applying the adult Braden Scale to children will produce unreliable risk stratification.

Reassessment frequency depends on the care setting. Acute care: on admission, then every 24-48 hours. ICU: every 24 hours minimum, or with any hemodynamic change. Long-term care: on admission, then weekly. Home health: on each nursing visit. Perioperative: preoperatively and within 24 hours postoperatively. Any significant clinical event - surgery, sepsis, prolonged hypotension, new incontinence - should trigger immediate re-scoring regardless of schedule.

The Braden Scale has a sensitivity of approximately 83% and specificity of 64% in general acute care (Bergstrom et al.). It does not account for several known risk factors: perfusion/oxygenation status, diabetes, corticosteroid use, anemia, previous pressure injuries, or surgical duration. It may overpredict risk in some populations (high false-positive rate), leading to resource overutilization. It should be used as one component of a comprehensive skin risk assessment, not as a standalone decision tool. Clinical judgment remains essential.